Last reviewed · How we verify
[14C]-linerixibat intravenous infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C]-linerixibat intravenous infusion ([14C]-linerixibat intravenous infusion) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C]-linerixibat intravenous infusion TARGET | [14C]-linerixibat intravenous infusion | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C]-linerixibat intravenous infusion CI watch — RSS
- [14C]-linerixibat intravenous infusion CI watch — Atom
- [14C]-linerixibat intravenous infusion CI watch — JSON
- [14C]-linerixibat intravenous infusion alone — RSS
Cite this brief
Drug Landscape (2026). [14C]-linerixibat intravenous infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-linerixibat-intravenous-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab